Adds details on executive board enlargement in last two paragraphs
FRANKFURT, Feb 18 (Reuters) - Germany's Merck KGaA MRCG.DE said on Tuesday its lab equipment division and its pharmaceuticals division would be under new leadership from June but it added that its strategy remains unchanged.
Jean-Charles Wirth is to become the CEO of the Life Science unit, a maker of gear and supplies for biotech labs, succeeding Matthias Heinzel, who has decided to not renew his contract.
Wirth currently heads the Science & Lab Solutions subunit within Life Science, the company said in a statement.
Danny Bar-Zohar, currently the head of drug research and development, will become CEO of the pharmaceuticals division, succeeding Peter Guenter, who has decided to retire from Merck, it added.
In addition, Khadija Ben Hammada will assume the newly created role of Chief People Officer on March 1, as Merck adds a sixth executive board seat.
She currently holds the title of Chief Human Resources Officer and will take on additional responsibilities in areas such as sustainability, compliance and site management of the headquarters in Darmstadt.
(Reporting by Ludwig Burger, editing by Rachel More)
((ludwig.burger@thomsonreuters.com; +49 30 220133634;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。